Opportunity Overview
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD
This is one of 7 active United States Clinical Trials opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | National Institutes of Health |
|---|---|
| Country | United States |
| Category | Clinical Trials |
| NAICS | 93.242 |
| Published | November 18, 2024 |
| Procurement stage | Request for Proposal (RFP) |
| Response due | September 07, 2026 |
| Status | Open — accepting responses |
| Official source | View original notice |
| Last verified | August 09, 2026 |
Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.
Related Opportunities in United States
See every United States Clinical Trials opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United States Clinical Trials intelligence report in your inbox
A personalized report on United States Clinical Trials opportunities, emailed in 5-10 minutes. One per month, no account needed.